Certified by Founder
Lodge
Mable | Neurolytic Healthcare
start up
United States
- San Francisco, California
- 27/07/2022
- Seed
- $3,200,000
Migraines are heritable. Uncover the link between your genetics and migraines to help prevent your migraine in advance and get medication delivered directly to your door.
- Industry Hospital & Health Care
- Website https://www.trymable.com/?utm_source=linkedin&utm_medium=social&utm_campaign=custom_button
- LinkedIn https://www.linkedin.com/company/mable-migraine-relief/
Related People
Roman RothaermelCo Founder
United Kingdom -
London, England
Before founding Mable, I was a researcher at the University of Oxford working at the intersection between neuroscience, data science and pharmacology. Today at Mable, we're using data-driven approaches to fight neurological conditions starting with migraines - a problem that affects 12% of the population and is in urgent need of innovation in care quality and delivery mechanisms.
Syntracts | $5,300,000 | (Oct 24, 2025)
GradBridge | $20,000,000 | (Oct 24, 2025)
Sumble | $38,500,000 | (Oct 24, 2025)
CipherOwl | $15,000,000 | (Oct 24, 2025)
Sizable Energy | $8,000,000 | (Oct 24, 2025)
Elevara Medicines | $70,000,000 | (Oct 24, 2025)
Vermeer | $10,000,000 | (Oct 24, 2025)
GammaTime | $14,000,000 | (Oct 24, 2025)
Cybrid | $10,000,000 | (Oct 24, 2025)
Apriority Financial, Inc. | $2,300,000 | (Oct 24, 2025)
OneAM | $4,700,000 | (Oct 24, 2025)
🌱 Rightcharge | $2,131,920 | (Oct 24, 2025)
Tensormesh | $4,500,000 | (Oct 24, 2025)